arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Innoviva, Inc.

INVA
$19.21 ▼ -2.04 (-9.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
83
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Innoviva, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.4B
Dividend Yield —
Revenue Growth 19.3% ↗
Op. Margin 42.5% ↗
ROIC 2.6% ↗
FCF / Share $0.70 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield 3.7%
Debt / Equity 0.21
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$119.59M
↑ +19.3% —
Net Income Profit after all expenses
$186.59M
— 0.0% —
Operating Margin Operating profit as % of sales
42.5%
↑ +9.2% 93th
FCF / Share Free cash flow per share
$0.70
↑ +49.6% —
Long-Term Debt Long-term obligations
$258.45M
— +0.1% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
97
Returns ↓
89
Financial Health ↓
76
Cash Quality ↓
50

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters